Skip to Main content Skip to Navigation
Journal articles

Estrogenic or Antiestrogenic Therapies for Multiple Myeloma?

Abstract : Multiple myeloma (MM) is a common hematological malignancy which remains incurable due to both intrinsic and acquired resistance to conventional or more novel drugs. Estrogenic and antiestrogenic compounds are very promising drugs for the treatment of MM. Indeed, they inhibit cell proliferation in vitro. They block cell cycle and/or induce apoptosis even in drug-resistant MM cells but not normal B cells. They interfere with survival pathways often deregulated in myelomas. They cooperate with conventional drugs to enhance apoptosis or to overcome resistance. In vivo, they act also on tumoral angiogenesis in xenograft models. As a whole, they possess all the criteria which render them attractive for a new therapeutic strategy. Importantly, they are well-tolerated at the doses tested in vitro or in vivo, encouraging the rapid onset of critical trials.
Document type :
Journal articles
Complete list of metadata

Cited literature [39 references]  Display  Hide  Download
Contributor : Université Normandie Connect in order to contact the contributor
Submitted on : Wednesday, July 24, 2019 - 3:13:35 PM
Last modification on : Sunday, June 26, 2022 - 12:11:44 PM


Publisher files allowed on an open archive


Distributed under a Creative Commons Attribution 4.0 International License




Brigitte Sola, Jack-Michel Renoir. Estrogenic or Antiestrogenic Therapies for Multiple Myeloma?. Molecular Cancer, BioMed Central, 2007, 6 (1), pp.59. ⟨10.1186/1476-4598-6-59⟩. ⟨hal-01762023⟩



Record views


Files downloads